Fragile X Syndrome Market Research Report 2022: Size & Trends, Epidemiology & Pipeline Analysis, Competitor Assessment, Unmet Need, Clinical Trial Strategies & Forecast, 2021-2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Fragile X Syndrome Market Size and Trends Report, Including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Strategies and Forecasts clinical trials, 2021-2030” has been added to the drug pipelines from ResearchAndMarkets.com offer.

The two clinically and commercially relevant segments considered for the classification of FXS in this report are segmented into three groups by age: pediatric patients 0-11 years old, adolescent patients 12-17 years old, and adult patients aged 12-17 years old. 18 years and over.

This report covers 2MM (US and Germany) and provides an Excel-based forecast model for the Fragile X syndrome market to 2030.

Highlights

  • The forecast includes two countries

  • The forecasts cover three periods: base year, 5 years and 10 years

  • There are currently no approved therapies available for FXS, so treatments prescribed are exclusively off-label products that target individual symptoms of the disease. The most frequently used classes of drugs are: selective serotonin reuptake inhibitors (SSRIs), psychostimulants, antipsychotics, anticonvulsants and antihypertensive anxiolytics.

  • Current treatment options that target the irritability and aggressiveness symptoms of FXS are often sedating and decrease patients’ interaction with their environment. This avoids disruptive behaviors but negatively affects the quality of life of patients. There is a need for interventions that suppress aggressive behavior without side effects.

  • Products in Phase I and II stages of development represent 89.7% of FXS’ pipeline, while limited development is seen in Phase III trials with only one drug currently in development.

  • The FXS market will show significant growth between 2020 and 2030, driven by the entry of four pipeline agents. Notably, sales of high-priced pipeline agents, Zygel, zatolmilast and trofinetide represent the most influential growth drivers.

Scope

  • Overview of FXS, including disease epidemiology, symptoms, diagnosis and management.

  • FXS Therapeutics Market annualized revenue, treatment cost per patient, and treatment utilization patterns in three patient segments (pediatric patients 0-11 years old, adolescent patients 12-17 years old, and adult patients aged 18 and over) planned from 2020 to 2030.

  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and the implications of these factors for the FXS therapies market.

  • Pipeline Analysis: Comprehensive data assessing emerging trends and mechanisms of action under development for FXS therapy. The most promising candidates in Phase III and Phase IIb development are profiled.

  • Analysis of the current and future competition in the global FXS therapeutics market. In-depth review of key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Main topics covered:

1. Summary

1.1 Executive Summary

2 Overview of the disease

2.1 Presentation of fragile X syndrome

2.2 SWOT Analysis of Fragile X Syndrome

2.3 Classification of fragile X syndrome

3 Epidemiology

3.1 Prevalent Diagnosed Cases of Fx, Male and Female, 2020-30

3.2 Sources and methodology

4 current treatment options

4.1 Treatment Paradigm

4.2 Current treatment options

4.3 Product Profile: Ssris (fluoxetine, sertraline, citalopram, escitalopram)

4.4 Product profile: other antidepressants (venlafaxine, bupropion, trazadone)

4.5 Product Profile: Psychostimulants (Methylphenidate Hydrochloride)

4.6 Product Profile: Atypical Antipsychotics (aripiprazole, risperidone)

4.7 Product Profile: Anticonvulsants (Lamotrigine, Carbamazepine, Sodium Valproate)

4.8 Product Profile: Antihypertensive Anxiolytics (Clonidine, Guanfacine)

4.9 Product Profile: Benzodiazepines (Clonazepam, Diazepam)

4.10 Product Profile: Lithium (lithium carbonate)

5 Unmet needs and opportunities

5.1 Unmet Needs in Fragile X Syndrome

6 R&D strategies

6.1 Trends in Trading in Fx

6.2 Trends in Trading in Fx

7 Pipeline assessment

7.1 Fragile X Syndrome Pipeline Overview

7.2 Late-stage pipeline agents

7.3 Product Profile: Zygel by Zynerba Pharmaceuticals

7.4 Product Profile: Zatolmilast from Tetra Therapeutics

7.5 Product Profile: Acamprosate Calcium Sr by Confluence Pharmaceuticals

7.6 Product Profile: Trofinetide from Neuren Pharmaceuticals and Acadia Pharmaceuticals

8 Market Outlook

8.1 Fragile X Syndrome Market Forecast

8.2 Market Drivers and Barriers

9 Appendix

Companies cited

  • Pharmaceuticals Acadia

  • Advanz Pharma Corp.

  • Boehringer Ingelheim

  • Pharmaceutical Confluence

  • Eli Lily

  • GlaxoSmithKline

  • H.Lundbeck

  • Janssen

  • Neuren Pharmaceuticals

  • Novartis

  • Otsuka Pharmaceuticals

  • Sanofi

  • Takeda

  • Viatris

  • Tetra Therapeutic

  • Zynerba Pharmaceuticals

For more information about this Drug Pipelines report, visit https://www.researchandmarkets.com/r/tw0iow

Comments are closed.